Form 4: Recursion Pharmaceuticals CEO Christopher Gibson Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Christopher Gibson, CEO of Recursion Pharmaceuticals, filed a Form 4 detailing transactions involving Class A Common Stock and stock options.
Summary
- Christopher Gibson, the CEO of Recursion Pharmaceuticals, filed a Form 4 with the SEC.
- The filing reports transactions related to Class A Common Stock, including acquisitions, disposals, and shares withheld for tax obligations.
- Gibson acquired 525,283 shares of Class A Common Stock at $0, vesting over time.
- He also acquired 16,809 shares of Class A Common Stock at $0, vesting immediately.
- 5,569 shares were disposed of at $7.25 to cover tax obligations.
- Following these transactions, Gibson directly owns 1,273,156 shares of Class A Common Stock.
- The filing also details stock options held by Gibson, including options to purchase 1,050,567 shares at $7.25, vesting over time, and other options at various prices and vesting schedules.
- Gibson also indirectly owns shares through LAHWRAN-3 LLC (486,000 shares), LAHWRAN-4 LLC (388,000 shares), and the Gibson Family Trust (67,875 shares).
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing. The CEO acquiring shares is mildly positive, but the disposal for tax obligations is mildly negative, balancing out overall.
Positives
- The acquisition of shares by the CEO could be interpreted as a positive signal about the company's prospects.
Negatives
- The disposal of shares to cover tax obligations could be seen as a minor negative, although it's a common practice.
Risks
- Changes in beneficial ownership, while routine, can sometimes signal shifts in management's confidence or strategy.
- The vesting schedules of stock options and RSUs could create future dilution.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting schedules of RSUs and stock options suggest ongoing equity-based compensation.
Industry Context
Form 4 filings are a routine part of corporate governance and provide transparency into the trading activities of company insiders. They are closely watched by investors for signals about management's view of the company's prospects.
Comparison to Industry Standards
- Stock option grants and RSU vesting schedules are common compensation practices in the pharmaceutical industry, used to align management's interests with those of shareholders.
- The specific terms of these grants (exercise prices, vesting schedules) are generally comparable to those offered by similar-sized biotech companies to their executives.
- Companies like Moderna, BioNTech, and Regeneron also utilize stock options and RSUs as part of their executive compensation packages.
Stakeholder Impact
- Shareholders can use this information to understand the CEO's stake in the company.
- Employees may be interested in the details of stock option and RSU grants as they relate to compensation practices.
Key Dates
| Date | Description |
|---|---|
| 02/04/2022 | Date related to vesting of stock options. |
| 03/01/2023 | Date related to vesting of stock options. |
| 02/01/2033 | Expiration date of stock options. |
| 02/04/2032 | Expiration date of stock options. |
| 12/30/2030 | Date related to vesting of stock options. |
| 02/03/2025 | Date of earliest transaction and grant date of RSU and stock options. |
| 02/05/2025 | Date of signature for the power of attorney. |
| 05/15/2025 | Initial vesting date for some of the RSUs. |
| 02/03/2035 | Expiration date of stock options. |
Keywords
Form 4, beneficial ownership, stock options, Class A Common Stock, Christopher Gibson, Recursion Pharmaceuticals, RXRX, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.